# Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

> **NCT00052611** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 23 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00052611
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052611, "Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00052611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*